|
1
|
Döhner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
National Cancer Institute (NCI), . Cancer
stat facts: Leukemia-acute myeloid leukemia. NCI; Bethesda, MD:
2020
|
|
3
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shah A, Andersson TML, Rachet B, Björkholm
M and Lambert PC: Survival and cure of acute myeloid leukaemia in
England, 1971–2006: A population-based study. Br J Haematol.
162:509–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thein MS, Ershler WB, Jemal A, Yates JW
and Baer MR: Outcome of older patients with acute myeloid leukemia:
An analysis of SEER data over 3 decades. Cancer. 119:2720–2727.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou J and Chng WJ: Identification and
targeting leukemia stem cells: The path to the cure for acute
myeloid leukemia. World J Stem Cells. 6:473–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wakao H, Gouilleux F and Groner B: Mammary
gland factor (MGF) is a novel member of the cytokine regulated
transcription factor gene family and confers the prolactin
response. EMBO J. 13:2182–2191. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kollmann S, Grausenburger R, Klampfl T,
Prchal-Murphy M, Bastl K, Pisa H, Knab VM, Brandstoetter T, Doma E,
Sperr WR, et al: A STAT5B-CD9 axis determines self-renewal in
hematopoietic and leukemic stem cells. Blood. 138:2347–2359. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pham HTT, Maurer B, Prchal-Murphy M,
Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A,
Kolbe T, Elabd M, et al: STAT5BN642H is a driver mutation for T
cell neoplasia. J Clin Invest. 128:387–401. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bandapalli OR, Schuessele S, Kunz JB,
Rausch T, Stütz AM, Tal N, Geron I, Gershman N, Izraeli S, Eilers
J, et al: The activating STAT5B N642H mutation is a common
abnormality in pediatric T-cell acute lymphoblastic leukemia and
confers a higher risk of relapse. Haematologica. 99:e188–e192.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kontro M, Kuusanmäki H, Eldfors S,
Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H,
Gjertsen BT, Itälä-Remes M, et al: Novel activating STAT5B
mutations as putative drivers of T-cell acute lymphoblastic
leukemia. Leukemia. 28:1738–1742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Küçük C, Jiang B, Hu X, Zhang W, Chan JK,
Xiao W, Lack N, Alkan C, Williams JC, Avery KN, et al: Activating
mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK
cells. Nat Commun. 6:60252015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajala HLM, Eldfors S, Kuusanmäki H, van
Adrichem AJ, Olson T, Lagström S, Andersson EI, Jerez A, Clemente
MJ, Yan Y, et al: Discovery of somatic STAT5b mutations in large
granular lymphocytic leukemia. Blood. 121:4541–4550. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kiel MJ, Velusamy T, Rolland D,
Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel
AB, et al: Integrated genomic sequencing reveals mutational
landscape of T-cell prolymphocytic leukemia. Blood. 124:1460–1472.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nicolae A, Xi L, Pittaluga S, Abdullaev Z,
Pack SD, Chen J, Waldmann TA, Jaffe ES and Raffeld M: Frequent
STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia.
28:2244–2248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ihle JN: The Stat family in cytokine
signaling. Curr Opin Cell Biol. 13:211–217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smithgall TE, Briggs SD, Schreiner S,
Lerner EC, Cheng H and Wilson MB: Control of myeloid
differentiation and survival by Stats. Oncogene. 19:2612–2618.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Coffer PJ, Koenderman L and de Groot RP:
The role of STATs in myeloid differentiation and leukemia.
Oncogene. 19:2511–2522. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Halim CE, Deng S, Ong MS and Yap CT:
Involvement of STAT5 in oncogenesis. Biomedicines. 8:3162020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dellomo AJ, Abbotts R, Eberly CL,
Karbowski M, Baer MR, Kingsbury TJ and Rassool FV: PARP1 PARylates
and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other
STAT5-activated cancers. Transl Oncol. 15:1012832022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scherr M, Chaturvedi A, Battmer K,
Dallmann I, Schultheis B, Ganser A and Eder M: Enhanced sensitivity
to inhibition of SHP2, STAT5, and Gab2 expression in chronic
myeloid leukemia (CML). Blood. 107:3279–3287. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nieborowska-Skorska M, Wasik MA, Slupianek
A, Salomoni P, Kitamura T, Calabretta B and Skorski T: Signal
transducer and activator of transcription (STAT)5 activation by
BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains
of BCR/ABL and is required for leukemogenesis. J Exp Med.
189:1229–1242. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Groot RP, Raaijmakers JA, Lammers JW,
Jove R and Koenderman L: STAT5 Activation by BCR-Abl Contributes to
Transformation of K562 Leukemia Cells. Blood. 94:1108–1112. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Spiekermann K, Bagrintseva K, Schwab R,
Schmieja K and Hiddemann W: Overexpression and constitutive
activation of FLT3 induces STAT5 activation in primary acute
myeloid leukemia blast cells. Clin Cancer Res. 9:2140–2150.
2003.PubMed/NCBI
|
|
25
|
Ikezoe T, Kojima S, Furihata M, Yang J,
Nishioka C, Takeuchi A, Isaka M, Koeffler HP and Yokoyama A:
Expression of p-JAK2 predicts clinical outcome and is a potential
molecular target of acute myelogenous leukemia. Int J Cancer.
129:2512–2521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Venugopal S, Bar-Natan M and Mascarenhas
JO: JAKs to STATs: A tantalizing therapeutic target in acute
myeloid leukemia. Blood Rev. 40:1006342020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen CY, Tsay W, Tang JL, Shen HL, Lin SW,
Huang SY, Yao M, Chen YC, Shen MC, Wang CH and Tien HF: SOCS1
methylation in patients with newly diagnosed acute myeloid
leukemia. Genes Chromosomes Cancer. 37:300–305. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper
S, Spolski R, Leonard WJ and Broxmeyer HE: Essential role of signal
transducer and activator of transcription (Stat)5a but not Stat5b
for Flt3-dependent signaling. J Exp Med. 192:719–728. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu B, Tian H and Zhou SY: Detection of
FLT3 gene and FLT3/ITD gene mutation in chronic myeloid leukemia
and its significance. Ai Zheng. 23:1218–1221. 2004.(In Chinese).
PubMed/NCBI
|
|
30
|
Kiyoi H, Naoe T, Nakano Y, Yokota S,
Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, et
al: Prognostic implication of FLT3 and N-RAS gene mutations in
acute myeloid leukemia. Blood. 93:3074–3080. 1999.PubMed/NCBI
|
|
31
|
Perl AE, Altman JK, Cortes J, Smith C,
Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, et al:
Selective inhibition of FLT3 by gilteritinib in relapsed or
refractory acute myeloid leukaemia: A multicentre, first-in-human,
open-label, phase 1–2 study. Lancet Oncol. 18:1061–1075. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wingelhofer B, Maurer B, Heyes EC,
Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P,
Ruge F, Park J, et al: Pharmacologic inhibition of STAT5 in acute
myeloid leukemia. Leukemia. 32:1135–1146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wingelhofer B, Neubauer HA, Valent P, Han
X, Constantinescu SN, Gunning PT, Müller M and Moriggl R:
Implications of STAT3 and STAT5 signaling on gene regulation and
chromatin remodeling in hematopoietic cancer. Leukemia.
32:1713–1726. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Elumalai N, Berg A, Rubner S, Blechschmidt
L, Song C, Natarajan K, Matysik J and Berg T: Rational development
of Stafib-2: A selective, nanomolar inhibitor of the transcription
factor STAT5b. Sci Rep. 7:8192017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Haftchenary S, Luchman HA, Jouk AO, Veloso
AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman
K, et al: Potent targeting of the STAT3 protein in brain cancer
stem cells: A promising route for treating glioblastoma. ACS Med
Chem Lett. 4:1102–1107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brachet-Botineau M, Polomski M, Neubauer
HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G and Gouilleux F:
Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling
in hematopoietic cancers. Cancers (Basel). 12:2402020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X, Sun Y, Pireddu R, Yang H, Urlam
MK, Lawrence HR, Guida WC, Lawrence NJ and Sebti SM: A novel
inhibitor of STAT3 homodimerization selectively suppresses STAT3
activity and malignant transformation. Cancer Res. 73:1922–1933.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He Y, Peng S, Wang J, Chen H, Cong X, Chen
A, Hu M, Qin M, Wu H, Gao S, et al: Ailanthone targets p23 to
overcome MDV3100 resistance in castration-resistant prostate
cancer. Nat Commun. 7:131222016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee J, Seong S, Kim JH, Kim K, Kim I,
Jeong BC, Nam KI, Kim KK, Hennighausen L and Kim N: STAT5 is a key
transcription factor for IL-3-mediated inhibition of RANKL-induced
osteoclastogenesis. Sci Rep. 6:309772016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sheng W, Yang F, Zhou Y, Yang H, Low PY,
Kemeny DM, Tan P, Moh A, Kaplan MH, Zhang Y and Fu XY: STAT5
programs a distinct subset of GM-CSF-producing T helper cells that
is essential for autoimmune neuroinflammation. Cell Res.
24:1387–1402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo Z, Wang A, Zhang W, Levit M, Gao Q,
Barberis C, Tabart M, Zhang J, Hoffmann D, Wiederschain D, et al:
PIM inhibitors target CD25-positive AML cells through concomitant
suppression of STAT5 activation and degradation of MYC oncogene.
Blood. 124:1777–1789. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fenaux P, Mufti GJ, Hellstrom-Lindberg E,
Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz
G, List A, et al: Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk
myelodysplastic syndromes: A randomised, open-label, phase III
study. Lancet Oncol. 10:223–232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cook AM, Li L, Ho Y, Lin A, Li L, Stein A,
Forman S, Perrotti D, Jove R and Bhatia R: Role of altered growth
factor receptor-mediated JAK2 signaling in growth and maintenance
of human acute myeloid leukemia stem cells. Blood. 123:2826–2837.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hoelbl A, Schuster C, Kovacic B, Zhu B,
Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et
al: Stat5 is indispensable for the maintenance of bcr/abl-positive
leukaemia. EMBO Mol Med. 2:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Walz C, Ahmed W, Lazarides K, Betancur M,
Patel N, Hennighausen L, Zaleskas VM and Van Etten RA: Essential
role for Stat5a/b in myeloproliferative neoplasms induced by
BCR-ABL1 and JAK2(V617F) in mice. Blood. 119:3550–3560. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yan D, Hutchison RE and Mohi G: Critical
requirement for Stat5 in a mouse model of polycythemia vera. Blood.
119:3539–3549. 2012. View Article : Google Scholar : PubMed/NCBI
|
